We were delighted to talk to Prof. Stefan Schreiber (University Hospital Schleswig-Holstein, Kiel, Germany) around his post hoc analysis of the SELECTION trial, investigating filgotinib in Ulcerative Colitis.
The abstract ‘Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial’ (Presentation no. OP07) was presented at the 17th Congress of ECCO, February 16-19, 2022!
Questions
- How are therapeutic goals evolving in the management of patients with UC? (0:16)
- Â Could you give us a brief overview of the SELECTION trial and its findings? (1:21)
-  What were the aims of your post-hoc analysis of the SELECTION trial data and how well was the composite endpoint achieved? (2:19)
- What will be the impact of these findings on future clinical trial design? (4:28)
Disclosures: Stefan Schreiber reports personal fees from Abbvie, Amgen, Arena, BMS, Biogen, Celltrion, Celgene, IMAB, Gilead, MSD, Mylan, Pfizer, Fresenius, Janssen, Takeda, Theravance, Provention Bio, Protagonist, Falk, Ferring, UCB, Sandoz/Hexal, Lilly & Galapagos.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ECCO-IBD virtual meeting 2022.
